Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Research Registry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    372 result(s) found for: Research Registry. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003662-14 Sponsor Protocol Number: GN17CA082 Start Date*: 2019-05-13
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, rand...
    Medical condition: People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-000487-15 Sponsor Protocol Number: CLSYN.1702 Start Date*: 2018-12-21
    Sponsor Name:Hamilton Health Sciences Corporation through its Population Health Research Institute
    Full Title: CLEAR SYNERGY (OASIS 9) A 2x2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with ST elevation myocARdial infarction/SYNERGY Stent Registry – Organization to Ass...
    Medical condition: ST segment Elevation Myocardial Infarction (STEMI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) CZ (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005159-15 Sponsor Protocol Number: DORI-NOS-1008 Start Date*: 2012-03-05
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: An Open-Label, Parallel-Group Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Patients 3 Months to 17 Years of Age, Inclusive
    Medical condition: Bacterial infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003084-21 Sponsor Protocol Number: cHL-PG01 Start Date*: 2020-01-13
    Sponsor Name:PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA
    Full Title: A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgki...
    Medical condition: Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005210-18 Sponsor Protocol Number: EFFIPEC01 Start Date*: 2021-03-28
    Sponsor Name:Uppsala University
    Full Title: EFFIPEC – Efficacy of Hyperthermic Intraperitoneal Chemotherapy Single-arm Phase I study, followed by an open-label, randomized, controlled registry-based Phase III trial
    Medical condition: Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002019-16 Sponsor Protocol Number: U-2015-030 Start Date*: 2016-09-06
    Sponsor Name:Uppsala Clinical Research center
    Full Title: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart Failure with Preserved Ejection Fraction, HFPEF
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005243-28 Sponsor Protocol Number: 212082PCR3010 Start Date*: 2012-03-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000319-30 Sponsor Protocol Number: SECTOR Start Date*: 2022-03-09
    Sponsor Name:Institut Klinické a Experimentální Medicíny
    Full Title: Assessment of association between 3rd dose of mRNA vaccine and risk of SARS-CoV-2 infection in kidney transplant recipients, safety and immunogenicity assessment.
    Medical condition: SARS-CoV-2 infection in kidney transplant recipients; safety, effectiveness and immunogenicity of 3rd dose of SARS-CoV-2 mRNA vaccine.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002185-40 Sponsor Protocol Number: LSH-21-001 Start Date*: 2022-10-06
    Sponsor Name:Landspitali - The National University Hospital of Iceland
    Full Title: Comparison of the Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion and Plasma Levels in Patients with Adenine Phosphoribosyltransferase Deficiency: A Clinical Trial
    Medical condition: Adenine phosphoribosyltransferase deficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001222-42 Sponsor Protocol Number: CAPSS-272 Start Date*: 2015-04-24
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: A double-blind trial comparing the efficacy, tolerability and safety of monotherapy topiramate versus phenytoin in subjects with seizures indicative of new onset epilepsy
    Medical condition: New onset epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001223-23 Sponsor Protocol Number: CAPSS-311 Start Date*: 2015-04-24
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: TOPAMAX (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX as Monotherapy in the Trea...
    Medical condition: New onset epilepsy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023952-10 Sponsor Protocol Number: GS-US-196-0140 Start Date*: 2011-06-27
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001735-22 Sponsor Protocol Number: CNTO328SMM2001 Start Date*: 2011-09-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma
    Medical condition: High-risk Smoldering Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028233 Multiple myeloma without mention of remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) GR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2024-000583-38 Sponsor Protocol Number: 70033093THR1011 Start Date*: 2024-12-20
    Sponsor Name:Janssen Research & Development, LLC
    Full Title: Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Ris...
    Medical condition: Thromboembolic Events
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10043565 Thromboembolic event LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-001077-40 Sponsor Protocol Number: T54/2015 Start Date*: 2019-05-07
    Sponsor Name:Turku University Hospital
    Full Title: INNOVATIVE STEROID TREATMENT TO REDUCE ASTHMA DEVELOPMENT IN CHILDREN AFTER FIRST-TIME RHINOVIRUS INDUCED WHEEZING – THE INSTAR STUDY
    Medical condition: First acute wheezing episode
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002296-17 Sponsor Protocol Number: GS-US-337-0121 Start Date*: 2013-09-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for ...
    Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004920-39 Sponsor Protocol Number: 38518168ASH2001 Start Date*: 2013-08-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003133-34 Sponsor Protocol Number: OSU1 Start Date*: 2012-02-29
    Sponsor Name:A. Carlsson Research AB
    Full Title: The Effects of the Dopamine Stabilizer (-)-OSU6162 on Craving and Impulsivity in Alcohol Dependent Patients
    Medical condition: Alcohol dependence
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001176-38 Sponsor Protocol Number: CNTO1959HDS2001 Start Date*: 2018-10-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Moderate to Severe Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10076650 Acne inversa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000975-33 Sponsor Protocol Number: RDCRN_RKSC_6412 Start Date*: 2013-11-19
    Sponsor Name:Landspitali - The National University Hospital of Iceland
    Full Title: Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1
    Medical condition: Adenine phosphoribosyltransferase deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 10 21:55:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA